Tanvex Takes A Hit On Trastuzumab With CRL In US
Filing For Herceptin Biosimilar Is Knocked Back By FDA
Tanvex has seen its application for a trastuzumab biosimilar knocked back by the US Food and Drug Administration, receiving a complete response letter over the filing.
